http://www.advfn.com/nasdaq/rss.asp?symbol=NBIX Neurocrine Biosciences Company Newsfeed en Mon, 18 Oct 2010 09:31:23 EDT Mon, 18 Oct 2010 09:31:23 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=NBIX&article=44827263&headline=neurocrine-biosciences-sees-positive-study-results-for-drug http://www.advfn.com/nasdaq/StockNews.asp?stocknews=NBIX&article=44827263&headline=neurocrine-biosciences-sees-positive-study-results-for-drug <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Neurocrine Biosciences Inc. (NBIX) said it saw "positive" results of a first-phase study of one of its compounds and added that it plans to initiate a second-phase study in patients with tardive dyskinesia--which causes involuntary, repetitive body... Mon, 18 Oct 2010 09:31:23 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=NBIX&article=43250460&headline=abbott-to-pay-neurocrine-up-to-575-million-in-endometriosis http://www.advfn.com/nasdaq/StockNews.asp?stocknews=NBIX&article=43250460&headline=abbott-to-pay-neurocrine-up-to-575-million-in-endometriosis <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Abbott Laboratories (ABT) has agreed to pay as much as $575 million as part of a deal to help develop and commercialize Neurocrine Biosciences Inc.'s (NBIX) endometriosis treatment. </p> <p> The deal follows Neurocrine's announcement last month of... Wed, 16 Jun 2010 07:16:14 EDT